Review names low engagement as the unsolved problem in digital obesity care
The review credits digital tools with widening access to obesity care while calling low engagement an unsolved problem; it tests no specific app built for GLP-1 users.
A review published September 10, 2026, in the journal Current Obesity Reports concludes that digital tools have widened access to obesity care and eased the work of tracking diet and activity, while naming low engagement as the field's unsolved problem [1]. The review covers mobile apps, wearables, telehealth and artificial intelligence, and it surveys existing evidence rather than reporting a new trial [1].
Mobile apps and wearables reduce the burden of behavior change strategies such as self-monitoring, and telehealth removes numerous barriers to in-person obesity care, the review states [1]. Even so, it says low engagement is a persistent problem with digitally delivered interventions [1]. Its summary calls for future research on ways to improve engagement, on adaptive interventions that respond to patients' evolving care needs, and on putting these tools into healthcare settings [1].
The review frames the scale of the problem. Obesity prevalence rose from 23% in 1988 to 42.5% in 2017, then leveled off for nearly 10 years [1]. Diet tracking apps — the first, Lose It, appeared in 2008 — were downloaded more than 3.6 billion times in 2024, and the global weight loss app market is worth $4.6 billion and is expected to double by 2034 [1]. Between 2015 and 2022, commercial digital lifestyle interventions became widely available and telehealth reimbursement rules were relaxed [1]. In 2021 the FDA approved semaglutide, a GLP-1 receptor agonist, for obesity; demand for anti-obesity medications then exploded and digital platforms to support medication users proliferated, according to the review [1].
Evidence on whether tracking apps themselves drive weight loss is mixed in the review's account. Early trials found the apps were not efficacious as standalone interventions [1]. Yet diet tracking is the strongest predictor of weight loss within lifestyle interventions, and adherence to tracking is generally low [1].
The review describes artificial intelligence as an emerging area, used to glean personalized insights from data collected by wearables and mobile apps and to deliver lifestyle coaching [1].
The review does not evaluate individual commercial apps, and it does not report randomized trials of features sold by apps built to accompany GLP-1 medications. Which specific products have been tested, and how they perform, has not been reported [1].
Why it matters for patients
For people deciding about obesity care, the review's practical message is that access and engagement are separate questions. Telehealth and apps can remove barriers such as travel and scheduling [1], but a tool only helps if it is used, and the review says sustained engagement is where digital interventions fall short [1]. The review does not say how much engagement is needed, which features improve it, or whether engagement differs between people taking GLP-1 medications and those who are not [1]. It also lists scalability, affordability and integration into the healthcare system as conditions for population-level impact, without reporting whether the GLP-1 app category meets them [1].
What happens next
The review sets research priorities rather than dated milestones: improving engagement, designing adaptive interventions, and implementing digital tools in healthcare settings [1]. It reports no scheduled trials and no timeline for the GLP-1 companion app category [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.